Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: Could standardization lead to improved utilization of imaging within the diagnostic pathway?

Journal of Magnetic Resonance Imaging

Volumn 37, Issue 1, 2013, Pages 48-58

  Dickinson, Louise ^a,b,c   Ahmed, Hashim U ^a   Allen, Clare ^b   Barentsz, Jelle O ^d   Carey, Brendan ^e   Futterer, Jurgen J ^d   Heijmink, Stijn W ^d   Hoskin, Peter ^f   Kirkham, Alex P ^b   Padhani, Anwar R ^f   Persad, Raj ^g   Puech, Philippe ^h   Punwani, Shonit ^b   Sohaib, Aslam ⁱ   Tombal, Bertrand ^j   Villers, Arnauld ^h   Emberton, Mark ^j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f MOUNT VERNON CANCER CENTRE   (United Kingdom)

^g UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^h UNIV LILLE   (France)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

more..

Author keywords

multiparametric MRI; prostate cancer; scoring systems

Indexed keywords

CANCER DIAGNOSIS; CANCER GRADING; CANCER LOCALIZATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HISTOLOGY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MULTIPARAMETRIC NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SCORING SYSTEM; STANDARDIZATION; TUMOR GROWTH; TUMOR VOLUME; VALIDATION STUDY;

BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; CONTRAST MEDIA; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL ONCOLOGY; PROSTATE; PROSTATIC NEOPLASMS; QUALITY CONTROL; ROC CURVE;

EID: 84872860275     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23689     Document Type: Review

References (70)

1. Kirkham AP, Emberton M, Allen C,. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50: 1163-1174.
2. Engelbrecht MR, Puech P, Colin P, Akin O, Lemaitre L, Villers A,. Multimodality magnetic resonance imaging of prostate cancer. J Endourol 2010; 24: 677-684.
3. Yamamura J, Salomon G, Buchert R, et al. Magnetic resonance imaging of prostate cancer: diffusion-weighted imaging in comparison with sextant biopsy. J Comput Assist Tomogr 2011; 35: 223-228.
4. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011; 196: 374-381.
5. Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009; 193: 1583-1591.
6. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011; 59: 962-977.
7. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259: 162-172.
8. Roethke M, Anastasiadis AG, Lichy M, et al. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2011 [Epub ahead of print].
9. Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16: 1875-1883.
10. Ahmed HU, Kirkham A, Arya M, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009; 6: 197-206.
11. Singh PB, Ahmed HU, Emberton M,. Active surveillance: is there a need for better risk stratification at the outset? J Clin Oncol 2010; 28: e513.
12. Kelloff GJ, Choyke P, Coffey DS, Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009; 192: 1455-1470.
13. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
14. Shimizu T, Nishie A, Ro T, et al. Prostate cancer detection: the value of performing an MRI before a biopsy. Acta Radiol 2009; 50: 1080-1088.
15. Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011: 108: E171-178.
16. desouza NM, Riches SF, Vanas NJ, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782.
17. D'Orsi CJ, Bassett LW, Berg WA, et al. Breast imaging reporting and data system: ACR BI-RADS-Mammography, 4th ed. Reston, VA: American College of Radiology; 2003.
18. Liberman L, Abramson AF, Squires FB, Glassman JR, Morris EA, Dershaw DD,. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories. AJR Am J Roentgenol 1998; 171: 35-40.
19. Schnall MD, Ikeda DM,. Lesion Diagnosis Working Group report. J Magn Reson Imaging 1999; 10: 982-990.
20. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
21. Baker JA, Kornguth PJ, Floyd CE Jr,. Breast imaging reporting and data system standardized mammography lexicon: observer variability in lesion description. AJR Am J Roentgenol 1996; 166: 773-778.
22. Baker JA, Kornguth PJ, Lo JY, Floyd CE Jr,. Artificial neural network: improving the quality of breast biopsy recommendations. Radiology 1996; 198: 131-135.
23. Lemaitre L, Puech P, Poncelet E, et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009; 19: 470-480.
24. Kayhan A, Fan X, Oommen J, Oto A,. Multi-parametric MR imaging of transition zone prostate cancer: imaging features, detection and staging. World J Radiol 2010; 2: 180-187.
25. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99: 786-793.
26. Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W,. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients. Eur J Radiol 2009; 77: 340-345.
27. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005; 29: 149-153.
28. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L,. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-2437.
29. Chen M, Dang HD, Wang JY, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008; 49: 602-610.
30. Weinreb JC, Blume JD, Coakley FV, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-33.
31. Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007; 42: 116-122.
32. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-458.
33. Mueller-Lisse U, Mueller-Lisse U, Scheidler J, Klein G, Reiser M,. Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists. Eur Radiol 2005; 15: 1826-1833.
34. Nogueira L, Wang L, Fine SW, et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 2010; 75: 472-477.
35. Jung JA, Coakley FV, Vigneron DB, et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708.
36. Westphalen AC, Coakley FV, Qayyum A, et al. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology 2008; 246: 177-184.
37. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S,. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152.
38. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 2007; 244: 184-195.
39. Arumainayagam N, Kumaar S, Ahmed HU, et al. Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int 2010; 106: 991-997.
40. Iwazawa J, Mitani T, Sassa S, Ohue S,. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011; 17: 243-248.
41. Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 caes with histopathological correlation. Eur Radiol 2011; 21: 188-196.
42. Weidner AM, Michaely HJ, Lemke A, et al. Value of multiparametric prostate MRI of the peripheral zone. Z Med Phys 2011; 21: 198-205.
43. Vilanova JC, Cornet J, Barcelo-Vidal C, et al. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy. Radiology 2009; 253: 135-143.
44. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K,. Prostate cancer detection with 3T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010; 31: 625-631.
45. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011; 259: 775-784.
46. Yakar D, Heijmink SWTPJ, Hulsbergen-van de Kaa CA, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla. Invest Radiol 2011; 46: 301-306.
47. Rastinehad AR, Baccala AA, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011; 185: 815-820.
48. Jung DC, Lee HJ, Kim SH, Choe GY, Lee SE,. Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: pattern analysis of seminal vesicle lesions. J Magn Reson Imaging 2008; 28: 144-150.
49. Fuchsjager MH, Shukla-Dave A, Hricak H, et al. Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int 2009; 104: 315-320.
50. Lazarus E, Mainiero MB, Schepps B, Koelliker SL, Livingston LS,. BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value. Radiology 2006; 239: 385-391.
51. Kumbhani SR, Coakley FV, McCulloch CE, et al. Endorectal MRI after radiation therapy: questioning the sextant analysis. J Magn Reson Imaging 2011; 33: 1086-1090.
52. King CR, Ferrari M, Brooks JD,. Prognostic significance of prostate cancer originating from the transition zone. Urol Oncol 2009; 27: 592-597.
53. Augustin H, Erbersdobler A, Graefen M, et al. Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate 2003; 55: 48-54.
54. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3T for detection-histopathologic correlation. Radiology 2010; 255: 89-99.
55. Girouin N, Mege-Lechevallier F, Tonina SA, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17: 1498-1509.
56. Mouraviev V, Mayes JM, Polascik TJ,. Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009; 6: 205-215.
57. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008; 72: S12-24.
58. Ahmed HU,. The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361: 1704-1706.
59. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-461.
60. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
61. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252: 449-457.
62. Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M,. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010; 106: 1607-1611.
63. Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU,. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2010; 14: 46-52.
64. Schiebler ML, Yankaskas BC, Tempany C, et al. MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. AJR Am J Roentgenol 1992; 158: 559-562.
65. Akin O, Riedl CC, Ishill NM, Moskowitz CS, Zhang J, Hricak H,. Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer. Eur Radiol 2010; 20: 995-1002.
66. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT,. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004; 232: 140-146.
67. Scheenen TWJ, Futterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging. A prospective multicenter validation study. Invest Radiol 2011; 46: 25-33.
68. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494.
69. ESUR prostate MR guidelines 2012., Barentsz JO, Richenberg J, Clements R, et al. Eur Radiol 2012; 22: 746-757.
70. Onik G, Miessau M, Bostwick DG,. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27: 4321-4326.